Towards development of treat to target (T2T) in childhood-onset systemic lupus erythematosus: PReS-endorsed overarching principles and points-to-consider from an international task force

2023/01/10 by Eve Mary Dorothy Smith, Eve Smith, Amita Aggarwal +38 · 21 citations
Medicine · #Systemic Lupus Erythematosus Research #Rheumatoid Arthritis Research and Therapies #Autoimmune and Inflammatory Disorders Research

paper · pdf · doi:10.1136/ard-2022-223328

Abstract

OBJECTIVES: Application of 'treat-to-target' (T2T) in childhood-onset systemic lupus erythematosus (cSLE) may improve care and health outcomes. This initiative aimed to harmonise existing evidence and expert opinion regarding T2T for cSLE. METHODS: An international T2T Task Force was formed of specialists in paediatric rheumatology, paediatric nephrology, adult rheumatology, patient and parent representatives. A steering committee formulated a set of draft overarching principles and points-to-consider, based on evidence from systematic literature review. Two on-line preconsensus meeting Delphi surveys explored healthcare professionals' views on these provisional overarching principles and points-to-consider. A virtual consensus meeting employed a modified nominal group technique to discuss, modify and vote on each overarching principle/point-to-consider. Agreement of >80% of Task Force members was considered consensus. RESULTS: The Task Force agreed on four overarching principles and fourteen points-to-consider. It was agreed that both treatment targets and therapeutic strategies should be subject to shared decision making with the patient/caregivers, with full remission the preferred target, and low disease activity acceptable where remission cannot be achieved. Important elements of the points-to-consider included: aiming for prevention of flare and organ damage; glucocorticoid sparing; proactively addressing factors that impact health-related quality of life (fatigue, pain, mental health, educational challenges, medication side effects); and aiming for maintenance of the target over the long-term. An extensive research agenda was also formulated. CONCLUSIONS: These international, consensus agreed overarching principles and points-to-consider for T2T in cSLE lay the foundation for future T2T approaches in cSLE, endorsed by the Paediatric Rheumatology European Society.

Cited by

• PReS-endorsed international childhood lupus T2T task force definition of childhood lupus low disease activity state (cLLDAS). [europepmc]
• Impact of puberty, sex determinants and chronic inflammation on cardiovascular risk in young people. [europepmc]
• Rhupus syndrome in the pediatric population: A comprehensive systematic literature review. [europepmc]
• Defining remission in childhood-onset lupus: PReS-endorsed consensus definitions by an international task force. [europepmc]
• Childhood-Onset Systemic Lupus Erythematosus (cSLE): An International Perspective. [europepmc]
• Active implementation of low disease activity state as a treatment endpoint in childhood-onset systemic lupus erythematosus in routine practice is both feasible and associated with better outcomes. [europepmc]
• Improving lupus care index documentation in patients with childhood-onset systemic lupus erythematosus. [europepmc]
• Contributors to organ damage in childhood lupus: corticosteroid use and disease activity. [europepmc]
• Implementation of the Lupus Low Disease Activity State in Pediatric Rheumatology Care: The Role of the Visual Analog Scale. [europepmc]
• Elevated serum interferon-α2 associates with activity and flare risk in juvenile-onset systemic lupus erythematosus. [europepmc]
• New Insights on Childhood Lupus Nephritis. [europepmc]
• Development of CARRA/PReS-endorsed consensus Core and Expanded Datasets in childhood-onset systemic lupus erythematosus for international registry-based research. [europepmc]
• Mortality in children and adolescents with autoimmune inflammatory rheumatic diseases admitted to the pediatric intensive care unit. [europepmc]
• CAR-T cell therapy for juvenile-onset autoimmune diseases: a promising future? [europepmc]
• Management of childhood-onset systemic lupus erythematosus (cSLE) over the last two decades in Spain. [europepmc]
• Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients With Systemic Lupus Erythematosus: A Multicenter, Open-Label Trial. [europepmc]
• Juvenile-onset Systemic Lupus Erythematosus: Recent Advances in Pathogenesis and Treatment. [europepmc]
• Prevalence and psychosocial correlates of depression, anxiety and stress among caregivers of children with childhood-onset systemic lupus erythematosus in China: a cross-sectional study. [europepmc]
• Mental health monitoring in adolescents with SLE: associations with lupus low disease activity state and remission. [europepmc]
• The 2026 British Society for Rheumatology guideline for the management of children, young people and adults with systemic lupus erythematosus. [europepmc]
• Childhood-Onset Systemic Lupus Erythematosus Research over the Past Decade in Japan [europepmc]

Related

• Systemic Lupus Erythematosus: New Diagnostic and Therapeutic Approaches
• EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update
• Clinical Presentation and Treatment of Childhood‐Onset Lupus Nephritis
• Ten tips in lupus nephritis management
• Lupus nephritis: redefining the treatment goals